Sarepta Therapeutics (SRPT) announced positive muscle biopsy results from its Phase 1/2 study of golodirsen Wednesday morning. The study achieved statistical significance on all primary and secondary biological endpoints.
from RTT - Before the Bell http://ift.tt/2wb7Iv8
via IFTTT
No comments:
Post a Comment